Target HbA1c for Knee Replacement
For elective knee replacement surgery, aim for a preoperative HbA1c <8% (<64 mmol/L) whenever possible. This is the clear recommendation from the most recent American Diabetes Association Standards of Care 1.
The Evidence-Based Threshold
The 2025 ADA guidelines explicitly state that the A1C goal for elective surgeries should be <8% 1. This represents the current gold standard recommendation from the highest-quality guideline source available. Earlier versions from 2023 and 2024 consistently maintained this same threshold 2, 3, 2, 3.
Why <8% Rather Than <7%?
While many clinicians traditionally aimed for HbA1c <7%, the evidence shows this stricter target may be counterproductive:
Achievability matters: Research demonstrates that only 59% of diabetic patients presenting with HbA1c >7% can actually achieve ≤7%, even after a median of 141 days of optimization 4. This creates significant access barriers to necessary surgery.
The <8% threshold is more realistic: When the threshold is set at 8%, approximately 70% of patients with initially elevated values can achieve the goal 4.
Clinical outcomes support <8%: The 2023 American College of Rheumatology/American Association of Hip and Knee Surgeons guideline conditionally recommends delaying surgery to improve glycemic control but deliberately avoids specifying a rigid threshold, acknowledging that optimal measures remain unclear 5.
Perioperative Glucose Management
Beyond the HbA1c target, maintain blood glucose 100-180 mg/dL (5.6-10.0 mmol/L) within 4 hours of surgery 1. Stricter perioperative targets (80-180 mg/dL) do not improve outcomes and increase hypoglycemia risk 2.
Critical Caveats
Do not use rigid HbA1c cutoffs as absolute barriers to surgery. The evidence supporting specific thresholds is indirect and very low quality 5. Consider these nuances:
Individual risk stratification: Research shows HbA1c has limited predictive utility for postoperative complications 6. One study found PJI thresholds of 9.7% for TKA and 7.8% for THA using Youden's J statistic, but with poor sensitivity (19-23%) 6.
Time-sensitive conditions: Patients with severe bone loss, deformity, or ligamentous instability should proceed without delay, as postponing surgery may worsen technical difficulty and outcomes 5.
Shared decision-making: Patients unable to achieve <8% despite optimization should be counseled about increased infection risk (particularly periprosthetic joint infection) but not automatically denied surgery 5, 7.
Practical Implementation
- Measure HbA1c preoperatively for all diabetic patients scheduled for knee replacement
- If HbA1c ≥8%: Refer to primary care or endocrinology for optimization
- Allow adequate time: Patients typically need 3-5 months to reduce HbA1c by 1-2% 4
- Reassess feasibility: If <8% proves unachievable after reasonable optimization efforts, proceed with informed consent about elevated risks rather than indefinitely delaying necessary surgery
- Optimize perioperative glucose control regardless of preoperative HbA1c, targeting 100-180 mg/dL
The <8% target balances risk reduction with surgical access, recognizing that perfect glycemic control may be unattainable for some patients who would otherwise benefit significantly from knee replacement.